GHK-Cu: Topical Evidence, Injectable Sales

What is GHK-Cu, and what has been tested in people?

GHK-Cu is the tripeptide glycyl-histidyl-lysine complexed with copper, identified in human plasma and carrying a topical cosmetic literature of its own ^[1]. Searched in September 2026 across three names, PubMed returns 197 indexed records, 71 tagged Humans, 3 under the clinical-trial publication type and 3 under the randomized type ^[4]. Split by route in the search itself, the names combined with skin, wound and cosmetic terms return 116 records and the same 3 trial-type records, while combined with injection terms they return 23 records, 3 of them tagged Humans and 0 under either trial type ^[4].

All three trial-type records were opened. One is a 2006 wound study in rabbits ^[4]. The other two are the entire human trial record of the molecule, and both applied it to skin: a 1992 venous-ulcer trial and a 2006 trial on laser-resurfaced skin ^{[5, 6]}. The filters were proved live against a control term in the same session, and the reference records the counts ^[4].

What did the two human trials find?

The 1992 trial randomized patients with venous stasis ulcers to a 0.4% copper tripeptide cream, to 1% silver sulfadiazine cream, or to an inert vehicle, with blinded evaluators; 86 evaluable patients completed it. Silver sulfadiazine reduced ulcer size more than either of the other two arms, and there was no difference between the copper tripeptide cream and the placebo ^[5].

The 2006 trial randomized patients undergoing circumoral carbon dioxide laser resurfacing to a post-treatment skin regimen with or without GHK-Cu; 13 patients completed it. Computer analysis and blinded evaluators found no statistically significant difference in the resolution of redness, and no difference between groups in wrinkles or overall skin quality; the one significant result was a questionnaire item on which patients using the product reported higher satisfaction (P = .04) ^[6].

So the topical record, read rather than summarized, is one negative trial against placebo and one small trial in which the objective measures were flat. The review literature describing the tripeptide's effects on collagen signaling and skin regeneration is built largely from cell culture and small cosmetic studies ^[1], and a 2026 review of peptide therapies for musculoskeletal and performance uses finds no clinical trial support for the injectable form ^[2]. None of that is the injected product's evidence, because the injected product has no evidence of its own.

What are the three injection-scoped human records?

They were opened, because three human-tagged records under an injection search is exactly the number a seller would round up to a trial. One is a biomaterials paper on polymer microspheres. One is a 2026 review written as a primer on injectable peptides for sports physicians. One is a 2018 pilot of a hair-growth formulation injected intradermally into the scalp ^[4]. Not one is a trial of injected GHK-Cu, and the injection-scoped search returns nothing at all under either trial publication type ^[4].

The gap between the two routes is therefore not a matter of degree. The topical literature has trials, thin and mostly negative; the injectable literature has none. A vial sold for regeneration is borrowing its evidence from a cream, and the cream's evidence is what the two paragraphs above describe. The trial record prints the counts beside every other molecule in the index.

Why is the topical product legal and the injectable not?

They are regulated under different parts of the same statute, and the dividing line is intended use. FDA states that cosmetic products and ingredients do not need premarket approval, with the exception of color additives; that the Federal Food, Drug, and Cosmetic Act defines a cosmetic by its intended use, as an article applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance; and that a product intended to treat or prevent disease or to affect the structure or function of the body is a drug even if it also affects the appearance ^[7]. A serum sold to smooth skin is a cosmetic. A vial sold to heal tissue is a drug, and a drug with no approval can lawfully be compounded only through the bulks-list process.

That process is where the injectable route stands today. FDA's list document records that GHK-Cu was removed from Category 1 of the interim 503A bulks list on April 22, 2026 because its nominations were withdrawn, that a nominator clarified on May 5, 2026 that it had meant to withdraw only the injectable route, and that GHK-Cu except for injectable routes will be added back to Category 1, where the document lists it; the injectable route was not put back and sits on no list, and FDA states it intends to consult its advisory committee about the substance before the end of February 2027 ^[3]. FDA's safety-risk page separately carries an entry for GHK-Cu for injectable routes among substances nominated but withdrawn, stating that compounded injectable drugs containing it may pose risk for immunogenicity and that there are limited data in humans to inform safety-related considerations ^[8]. Drugs@FDA holds no application under the name, while the identical query returned an approved application for a control term in the same run ^[9].

Two FDA documents describe the same withdrawal with different category language, and both are cited here as written ^{[3, 8]}. What neither document leaves open is the position of the injectable form: no category, no approval, no lawful compounding route, and a written FDA statement that the human data are limited. The research-only page explains why leaving a list is not permission, and the nomination tracker files the substance by what became of its nomination.

Where does that leave a buyer?

With a cosmetic that is legal, lightly evidenced and unremarkable, and an injectable that is none of those. Material sold under the name for injection is research-use-only chemical supply, produced and sold outside pharmacy licensure and quality standards; the research-use-only entry sets out what that posture does and does not mean. The monograph carries the dated regulatory ledger, and the repair peptides class sets this molecule beside BPC-157 and TB-500, both of which appear on the July 2026 committee agenda in the vote ledger, and both of which share with it a human record that does not contain the use they are sold for.

Elsewhere in this index